Published in Drug Week, October 18th, 2002
ISA(TX)247 is being developed under a global collaboration agreement with Roche.
The phase II trial is a randomized, open label study of ISA(TX)247 and cyclosporine A in stable kidney transplant patients who are at least 6 months postoperative. The 12-week study is being conducted at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.